WO2015194764A3 - 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 - Google Patents
피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 Download PDFInfo
- Publication number
- WO2015194764A3 WO2015194764A3 PCT/KR2015/005118 KR2015005118W WO2015194764A3 WO 2015194764 A3 WO2015194764 A3 WO 2015194764A3 KR 2015005118 W KR2015005118 W KR 2015005118W WO 2015194764 A3 WO2015194764 A3 WO 2015194764A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- alk
- pyrimidine
- effective ingredient
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/319,151 US10053458B2 (en) | 2014-06-17 | 2015-05-21 | Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient |
EP15809090.2A EP3159338A4 (en) | 2014-06-17 | 2015-05-21 | Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient |
CN201580032624.4A CN106459007B (zh) | 2014-06-17 | 2015-05-21 | 嘧啶-2,4-二胺衍生物及包含其作为有效成分的抗癌用药学组合物 |
JP2016573780A JP6622726B2 (ja) | 2014-06-17 | 2015-05-21 | ピリミジン‐2,4‐ジアミン誘導体及びそれを有効成分として含有する抗癌用医薬組成物 |
CA2952787A CA2952787A1 (en) | 2014-06-17 | 2015-05-21 | Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2014-0073555 | 2014-06-17 | ||
KR20140073555 | 2014-06-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015194764A2 WO2015194764A2 (ko) | 2015-12-23 |
WO2015194764A3 true WO2015194764A3 (ko) | 2016-04-14 |
Family
ID=54936206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2015/005118 WO2015194764A2 (ko) | 2014-06-17 | 2015-05-21 | 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10053458B2 (ko) |
EP (1) | EP3159338A4 (ko) |
JP (1) | JP6622726B2 (ko) |
KR (2) | KR101733733B1 (ko) |
CN (1) | CN106459007B (ko) |
CA (1) | CA2952787A1 (ko) |
WO (1) | WO2015194764A2 (ko) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101937529B1 (ko) * | 2016-07-26 | 2019-01-14 | 한국화학연구원 | 신규한 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
JP7025426B2 (ja) * | 2016-11-30 | 2022-02-24 | アリアド ファーマシューティカルズ, インコーポレイテッド | 造血前駆体キナーゼ1(hpk1)阻害剤としてのアニリノピリミジンas |
JOP20190281A1 (ar) | 2017-06-13 | 2019-12-02 | Korea Res Inst Chemical Tech | مشتق n2، n4 ثنائي فينيل بيريميدين -2، 4- ثنائي أمين، وطريقة لتحضيره، وتركيبة صيدلانية تحتوي على المشتق بوصفه مكون فعال للوقاية من السرطان أو علاجه |
KR102063155B1 (ko) | 2018-04-11 | 2020-01-08 | 한국과학기술연구원 | 우수한 카이네이즈 저해 활성을 보이는 다양한 치환기를 갖는 피리미딘 유도체 |
CN111171017B (zh) * | 2018-11-09 | 2021-12-24 | 天津大学 | 基于嘧啶的衍生物及其制备方法和应用 |
CN109593065A (zh) * | 2018-12-03 | 2019-04-09 | 重庆医科大学 | 一类hdac/alk双靶点抑制剂及其制备方法与应用 |
EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
BR112022011834A2 (pt) * | 2019-12-16 | 2022-08-30 | Korea Res Inst Chemical Tech | Derivado de pirimidina e uso do mesmo |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CA3171187A1 (en) * | 2020-02-14 | 2021-08-19 | Salk Institute For Biological Studies | Inhibitors of ulk1/2 and methods of using same |
CN112168773A (zh) * | 2020-08-13 | 2021-01-05 | 重庆医药高等专科学校 | 含嘧啶-2,4-二胺衍生物的抗癌用药物的制备方法 |
KR20220090443A (ko) * | 2020-12-21 | 2022-06-29 | 주식회사 비투에스바이오 | 헤테로아릴 유도체 화합물 및 이의 용도 |
CN116444488A (zh) * | 2022-01-14 | 2023-07-18 | 上海立森印迹医药技术有限公司 | 一种嘧啶-2,4-二胺衍生物及其制备方法和用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008073687A2 (en) * | 2006-12-08 | 2008-06-19 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
WO2009126515A1 (en) * | 2008-04-07 | 2009-10-15 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
US8148391B2 (en) * | 2006-10-23 | 2012-04-03 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors |
WO2012106540A1 (en) * | 2011-02-02 | 2012-08-09 | Irm Llc | Methods of using alk inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2611032C (en) | 2005-05-25 | 2012-01-17 | Genesense Technologies Inc. | 2-indolyl imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer |
EP2537830A1 (en) * | 2006-12-08 | 2012-12-26 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
HUE035029T2 (en) | 2008-05-21 | 2018-03-28 | Ariad Pharma Inc | Kinase inhibitor phosphorus derivatives |
WO2012125603A1 (en) * | 2011-03-16 | 2012-09-20 | Cephalon, Inc. | Macrocyclic compounds as alk, fak and jak2 inhibitors |
-
2015
- 2015-05-21 CN CN201580032624.4A patent/CN106459007B/zh not_active Expired - Fee Related
- 2015-05-21 EP EP15809090.2A patent/EP3159338A4/en not_active Withdrawn
- 2015-05-21 JP JP2016573780A patent/JP6622726B2/ja active Active
- 2015-05-21 KR KR1020150071257A patent/KR101733733B1/ko active IP Right Grant
- 2015-05-21 US US15/319,151 patent/US10053458B2/en active Active
- 2015-05-21 CA CA2952787A patent/CA2952787A1/en not_active Abandoned
- 2015-05-21 WO PCT/KR2015/005118 patent/WO2015194764A2/ko active Application Filing
-
2017
- 2017-02-28 KR KR1020170025934A patent/KR20170027757A/ko active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8148391B2 (en) * | 2006-10-23 | 2012-04-03 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors |
WO2008073687A2 (en) * | 2006-12-08 | 2008-06-19 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
WO2009126515A1 (en) * | 2008-04-07 | 2009-10-15 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
WO2012106540A1 (en) * | 2011-02-02 | 2012-08-09 | Irm Llc | Methods of using alk inhibitors |
Non-Patent Citations (2)
Title |
---|
OTT, G. R. ET AL.: "Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with in Vivo Antitumor Activity", ACS MEDICINAL CHEMISTRY LETTERS, vol. 1, no. 9, 2010, pages 493 - 498, XP055373321 * |
See also references of EP3159338A4 * |
Also Published As
Publication number | Publication date |
---|---|
US20170145007A1 (en) | 2017-05-25 |
CA2952787A1 (en) | 2015-12-23 |
JP2017518336A (ja) | 2017-07-06 |
KR101733733B1 (ko) | 2017-05-11 |
EP3159338A4 (en) | 2018-01-24 |
WO2015194764A2 (ko) | 2015-12-23 |
EP3159338A2 (en) | 2017-04-26 |
CN106459007A (zh) | 2017-02-22 |
JP6622726B2 (ja) | 2019-12-18 |
US10053458B2 (en) | 2018-08-21 |
CN106459007B (zh) | 2020-02-28 |
KR20170027757A (ko) | 2017-03-10 |
KR20150145176A (ko) | 2015-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015194764A3 (ko) | 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 | |
MX2019014548A (es) | Derivado de n2,n4-difenilprimidin-2,4-diamina, metodo para la preparacion del mismo, y una composicion farmaceutica que contiene el mismo como ingrediente activo para la prevencion o tratamiento de cancer. | |
PH12019500521A1 (en) | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
WO2016142855A3 (en) | Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors | |
WO2016196776A3 (en) | Inhibitors of bruton's tyrosine kinase | |
WO2016004305A3 (en) | Inhibitors of bruton's tyrosine kinase | |
WO2015070224A3 (en) | Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
WO2016044556A3 (en) | Arginine methyltransferase inhibitors and uses thereof | |
WO2015048689A8 (en) | Inhibitors of bruton's tyrosine kinase | |
WO2016126085A3 (ko) | 헤테로 고리 화합물 및 그를 포함하는 약제학적 조성물 | |
WO2014194254A9 (en) | Treatment of cancers using pi3 kinase isoform modulators | |
WO2015195848A8 (en) | Ezh2 inhibitors for treating lymphoma | |
MX2016002580A (es) | Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas. | |
WO2018011351A3 (en) | Kras inhibitor for use in treating cancer | |
PH12019502601A1 (en) | Therapeutic compounds and compositions, and methods of use thereof | |
MX2021008432A (es) | Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal. | |
EP3279210A4 (en) | Peptide having anticancer activity, and pharmaceutical composition and dietary supplement composition for preventing and treating cancer, both of which contain same as active ingredient | |
MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
WO2018027084A3 (en) | Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer | |
PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
WO2016073771A3 (en) | Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors | |
EP4282414A3 (en) | Modified release tablet formulations containing phosphodiesterase inhibitors | |
MX2021008667A (es) | Derivado de pirrolopirimidina y composición farmacéutica para prevenir o tratar enfermedades relacionadas con la proteína quinasa que comprende el mismo como principio activo. | |
WO2018054989A9 (en) | Benzoimidazole derivatives as anticancer agents | |
PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15809090 Country of ref document: EP Kind code of ref document: A2 |
|
REEP | Request for entry into the european phase |
Ref document number: 2015809090 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15319151 Country of ref document: US Ref document number: 2015809090 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016573780 Country of ref document: JP Kind code of ref document: A Ref document number: 2952787 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |